🔗 Share this article

Given that America continues making sweeping revisions to its vaccination recommendations, a particular individual has emerged unexpectedly: Høeg, an American of Danish descent physician and public health researcher who first made her name by casting doubt on Covid shots throughout the pandemic and has concentrated on alleged deaths after COVID-19 immunization in her brief tenure at the FDA.

Proposed Changes to Childhood Immunization Program

Agency leaders planned to announce sweeping revisions to the childhood immunization program recently, aligning the US with Denmark’s immunization schedule, according to reports – a significant shift that would put the US out of step with many the international standard with little proof for benefit. This reveal has been delayed until the next year.

Rather than Vinay Prasad, Høeg is scheduled to present at the event. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth appointee to head the division this calendar year.

A Shift at the Regulatory Body

The acting appointment may indicate a strengthened alliance between the drug and vaccine divisions as Høeg and Prasad solidify control at the agency – and it signals a renewed priority upon rolling back long-standing immunizations at the FDA.

Dr. Høeg has often pushed for ending certain pediatric vaccine recommendations in the US so as to align more in line with the Danish model, a country with nationalized medicine and a citizenry about the size of Wisconsin’s.

So far statements, she has continued to focus on vaccination policy – typically the domain of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Doubts Over Background

Høeg has no obvious experience in medication creation, oversight or administrative roles, which has been customary for former heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the commissioner and CBER since earlier this year.

“She appears not to have any of the qualifications” for overseeing the drug-regulation department, remarked a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She is not versed in leading a major agency. She has no expertise in industry regulation.”

Past directors of CBER would “grasp regulatory frameworks and the research of medication creation”, noted Janet Woodcock. “Clearly, she has not acquired the type of experience that former directors who ran the center have had.”

CDER has an enormous workload at the FDA, Woodcock pointed out.

“The public just zeroes in on the innovative therapies, but the off-patent medication office clears a multitude of off-brand pharmaceuticals. There’s a biosimilars program, over-the-counter program and more, and all of those have to be managed,” Woodcock noted. “The responsibility you neglect, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a major management aspect to the role, which manages in excess of 5,000 personnel. “It’s a huge management job, if you do it right,” the former official said.

Agency Reaction and Disputed Programs

In response to concerns about Dr. Høeg's credentials and whether this assignment signifies greater collaboration among FDA leaders on vaccines, a representative responded that the “inquiries are based on inaccurate presumptions”.

“This background is consistent with the responsibilities of her position,” the representative explained, citing the months Dr. Høeg spent advising the agency head on “drug safety and approval science, including computational safety modeling and shot safety tracking”.

As acting director, Høeg assumes responsibility for the commissioner’s recently launched fast-track approval initiative, a disputed one-day drug-approval program that reportedly troubled her preceding directors. “How are these medications being picked for this fast-track system? Who is making the calls?” Dr. Howard said. “There is a lot of secrecy happening at the regulatory body right now.”

Overall, he remarked, “the FDA looks to be trending towards less stringent regulations of most medications, aside from shots.”

Established History on Vaccines

Regarding vaccines, Dr. Høeg has a more documented, if troubling, past, critics observe. She released a analysis using unverified public submissions to determine the incidence of myocarditis after Covid immunization. She consulted for the Florida top health official Dr. Joseph Ladapo, who allegedly have changed statistics to suggest Covid vaccinations are riskier than they are.

Among her “wish list” for the incoming administration encompassed revising regulations for new vaccines and discontinuing “unnecessary” vaccines, she stated after the election on a audio program. At the agency, Høeg has reportedly floated the idea of preventing adolescent males from getting Covid vaccinations.

“She’s an thorough dogmatist who starts off with her preconceived notions and reverse-engineers to accommodate the science in a very misleading, fraudulent manner,” Howard said.

Taking Control and a “Push for Payback”

Dr. Høeg joined other skeptics, {like|